封面
市場調查報告書
商品編碼
1606524

日本核子醫學市場 - 2024-2031

Japan Nuclear Medicine Market - 2024-2031

出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

日本核子醫學市場在 2023 年達到 5.503 億美元,預計到 2031 年將達到 25.432 億美元,2024-2031 年預測期間複合年成長率為 21.2%。

核子醫學是利用放射性示蹤劑(稱為放射性藥物)來評估身體功能並診斷或治療疾病的醫學專業。專用影像相機使醫生能夠監測這些放射性示蹤劑在體內的運動。核子醫學中最受歡迎的兩種影像技術是單光子發射電腦斷層掃描 (SPECT) 和正電子發射斷層掃描 (PET) 掃描。

SPECT 影像設備產生3D(斷層掃描)影像,顯示引入病患體內的放射性追蹤劑分子的分佈。這些 3D 影像是透過電腦處理從身體周圍各個角度捕獲的大量投影影像而創建的。 SPECT 成像儀配備了伽馬相機探測器,可識別對患者施用的示踪劑發出的伽馬射線。

PET 掃描也利用放射性藥物產生3D影像。 SPECT 和 PET 掃描之間的主要區別在於所使用的放射性追蹤劑的類型。 SPECT 掃描可偵測伽瑪射線,而 PET 掃描中使用的放射性追蹤劑在衰變時產生稱為正電子的小粒子。正電子是一種質量與電子相似但帶有相反電荷的粒子。這些因素推動了日本核子醫學市場的擴張。

市場動態:

驅動程式和限制

癌症和心臟病的盛行率不斷增加

癌症和心臟病患病率的不斷上升極大地推動了日本核醫學市場的成長,預計將在整個市場預測期內推動成長。

癌症和心血管疾病發生率的增加是核醫市場成長的重要催化劑。隨著這些健康狀況變得更加普遍,對有效的診斷和治療方案的需求不斷增加。核子造影技術,特別是正子斷層掃描(PET)和單光子發射電腦斷層掃描(SPECT)在這些疾病的早期檢測和治療計劃中發揮著至關重要的作用。

日本是全球預期壽命最高的國家之一。自 20 世紀中葉以來,隨著傳染病死亡率的下降,預期壽命的增加可歸因於多種因素。其中包括由於全民健康保險而可以獲得的先進醫療技術、定期健康檢查和心血管疾病和癌症篩檢等公共衛生舉措,以及堅持傳統飲食和健康的生活方式。

然而,心血管疾病和癌症帶來的挑戰仍然嚴峻,並且在日本呈上升趨勢。儘管這些疾病的長期患者預後有了顯著改善,但癌症仍然是死亡的主要原因,緊隨其後的是心血管疾病。此外,這些疾病的發生率正在增加,特別是在老齡化人口中,這引起了人們對癌症治療引起的心血管併發症的擔憂,這些併發症可能會影響患者和倖存者的臨床結果和生活品質。

隨著癌症治療的進展,核醫市場越來越重視標靶放射性藥物 (TRP),以應對一系列腫瘤學和非腫瘤學應用。 TRP 是由多種成分組成的先進治療劑,包括靶向分子、連接劑、螯合劑和放射性核素,它們共同作用,直接向表達特定分子標靶的細胞提供集中治療。

根據世界衛生組織 2022 年的資料,日本的癌症統計數據揭示了重大的公共衛生挑戰,新增病例 1,005,157 例,死亡 426,278 例,流行病例 2,741,718 例(過去五年)。隨著對先進核醫學解決方案的需求不斷成長,該市場的利益相關者必須優先考慮創新、研究和合作,以有效滿足這些緊迫的醫療保健需求。

此外,關鍵參與者的策略(例如夥伴關係和合作)將推動日本核醫學市場。例如,2023 年 3 月,國際原子能總署 (IAEA) 最近與日本大學和科研機構的 11 名成員組成的聯盟簽署了一項協議,作為其「希望之光」計劃的一部分。該計劃旨在增強亞太地區的核醫學隊伍,滿足該地區日益成長的改善癌症護理的需求。

此外,2023 年 3 月,專注於核醫學的日本新創企業 Advanced Medical Science-Planning (AMS) 宣布與京都大學開展一項合作研究計畫。此次合作旨在將 Gallium-68 DOTATOC (68Ga-DOTATOC)(一種針對生長抑素受體的放射性藥物)引入日本醫療保健市場。這些因素都對日本核子醫學市場提出了需求。

此外,對標靶放射性藥物開發的需求不斷成長,有助於日本核醫學市場的擴張。

放射性藥物成本高

與核子醫學程序(包括影像和治療技術)相關的高成本對患者的可及性構成了重大障礙。核子醫學手術會產生各種成本,例如先進影像設備(如 PET 和 SPECT 機器)、放射性藥物的生產和採購以及專業設施的營運費用。這些手術的費用可能從數百美元到數千美元不等,具體取決於其複雜程度和類型。這種定價的可變性可能會阻礙患者進行必要的診斷測試或治療。

據報道,診斷影像、放射學和核子醫學設備的平均價格為 58,657 美元。該數字反映了與獲取醫療診斷中使用的各種類型的影像技術相關的一般成本。

高昂的費用可能會限制患者的就診,特別是來自低收入背景或醫療資源有限地區的患者。許多患者可能難以支付自付費用,或者可能沒有足夠的核醫手術保險,導致在獲得重要診斷和治療服務方面存在不平等。

核子醫學經常與 MRI 和 CT 掃描等其他影像技術競爭,儘管這些技術成本高昂,但可能被認為是更實惠的選擇。此外,相信非輻射影像方法更安全可以進一步減少對核醫學服務的需求,特別是在對成本敏感的人群中。因此,上述因素可能限制日本核醫市場的潛在成長。

目錄

第 1 章:方法與範圍

第 2 章:定義與概述

第 3 章:執行摘要

第 4 章:動力學

  • 影響因素
    • 促進要素
      • 癌症和心臟病的盛行率不斷增加
    • 限制
      • 放射性藥物成本高
    • 機會
    • 影響分析

第 5 章:產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 專利分析
  • 監管分析
  • SWOT分析
  • 未滿足的需求

第 6 章:依產品類型

  • 通用和診斷設備
  • 診斷
    • 單光子發射電腦斷層掃描 (SPECT)
    • 锝-99m (Tc-99m)
    • 鉈-201 (Tl-201)
    • 鎵 67 (Ga-67)
    • 碘 123 (I-123)
    • 其他
    • 正子斷層掃描 (PET)
    • 氟18 (F-18)
    • 銣-82 (Rb-82)
    • 其他
  • 療法
    • 阿爾法發射器
    • 鐳223 (Ra-223)
    • 其他
    • 貝塔發射器
    • 碘 131 (I-131)
    • 釔90 (Y-90)
    • 镥 177 (Lu-177)
    • 其他
    • 近距離放射治療同位素
    • 銫131
    • 碘125
    • 鈀103
    • 銥192
    • 其他

第 7 章:透過程序容量評估

  • 診斷程序
    • SPECT 程式
    • 正子斷層掃描程序
  • 治療程序

第 8 章:按申請

  • 心臟病學
  • 腫瘤學
  • 神經病學
  • 甲狀腺疾病
  • 內分泌腫瘤
  • 淋巴瘤和骨轉移
  • 肺部掃描
  • 泌尿科
  • 其他

第 9 章:最終用戶

  • 醫院
  • 診斷中心
  • 其他

第 10 章:競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章:公司簡介

  • GE Healthcare
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
  • Siemens Healthineers
  • Bracco
  • CANON MEDICAL SYSTEMS CORPORATION
  • Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
  • ATOX CO., Ltd.
  • IBA Radiopharma Solutions
  • JFE Engineering Corporation
  • Koninklijke Philips NV

第 12 章:附錄

簡介目錄
Product Code: PH8821

Overview

The Japan nuclear medicine market reached US$ 550.3 million in 2023 and is expected to reach US$ 2,543.2 million by 2031, growing at a CAGR of 21.2 % during the forecast period 2024-2031.

Nuclear medicine is a medical specialty that utilizes radioactive tracers, known as radiopharmaceuticals, to evaluate bodily functions and diagnose or treat diseases. Specialized imaging cameras enable physicians to monitor the movement of these radioactive tracers within the body. The two most prevalent imaging techniques in nuclear medicine are Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scans.

SPECT imaging devices generate three-dimensional (tomographic) images showing the distribution of radioactive tracer molecules introduced into a patient's body. These 3D images are created by computer processing a multitude of projection images captured from various angles around the body. SPECT imagers are equipped with gamma camera detectors that can identify the gamma-ray emissions from the tracers that have been administered to the patient.

PET scans also utilize radiopharmaceuticals to generate three-dimensional images. The primary distinction between SPECT and PET scans lies in the types of radiotracers employed. SPECT scans detect gamma rays, whereas the radiotracers used in PET scans produce small particles known as positrons upon decay. A positron is a particle that has a mass similar to that of an electron but carries an opposite charge. These factors have driven Japan nuclear medicine market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Cancer and Cardiac Disorders

The increasing prevalence of cancer and cardiac disorders is significantly driving the growth of the Japan nuclear medicine market and is expected to drive throughout the market forecast period.

The increasing incidence of cancer and cardiovascular diseases serves as a significant catalyst for the groth of the nuclear medicine market. As these health conditions become more widespread, there is a rising demand for effective diagnostic and therapeutic options. Nuclear imaging techniques, particularly Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) play a crucial role in the early detection and treatment planning for these diseases.

Japan boasts one of the highest life expectancies globally. The improvement in life expectancy since the mid-20th century, following a decline in mortality from communicable diseases, can be attributed to various factors. These include advanced medical technologies that are accessible due to universal health insurance, public health initiatives like routine health check-ups and screenings for cardiovascular diseases and cancer, and adherence to a traditional diet along with a healthy lifestyle.

However, the challenges posed by cardiovascular diseases and cancer remain significant and are on the rise in Japan. Despite notable improvements in long-term patient outcomes for these conditions, cancer continues to be the leading cause of death, followed closely by cardiovascular diseases. Furthermore, the incidence of these diseases is increasing, particularly among the aging population, raising concerns about cardiovascular complications resulting from cancer treatments that can affect clinical outcomes and quality of life for patients and survivors.

As cancer treatment progresses, the nuclear medicine market is placing greater emphasis on targeted radiopharmaceuticals (TRPs) to tackle a range of oncology and non-oncology applications. TRPs are advanced therapeutic agents that consist of multiple components, including a targeting molecule, linker, chelating agent, and radionuclide, which work together to deliver focused treatment directly to cells that express specific molecular targets.

According to the WHO data in 2022, in Japan, the cancer statistics reveal a significant public health challenge, with 1,005,157 new cases, 426,278 deaths, and 2,741,718 prevalent cases (over the past five years). As the demand for advanced nuclear medicine solutions rises, stakeholders in this market must prioritize innovation, research, and collaboration to effectively address these urgent healthcare needs.

Furthermore, key player's strategies such as partnerships and collaborations would drive the Japan nuclear medicine market. For instance, in March 2023, the International Atomic Energy Agency (IAEA) recently signed an agreement with an 11-member consortium of universities and scientific institutions in Japan as part of its Rays of Hope initiative. This initiative aims to enhance the nuclear medicine workforce across Asia and the Pacific, addressing the growing need for improved cancer care in the region.

Also, in March 2023, Advanced Medical Science-Planning (AMS), a Japanese start-up focused on nuclear medicine, announced a collaborative research initiative with Kyoto University. This partnership aims to introduce Gallium-68 DOTATOC (68Ga-DOTATOC), a radiopharmaceutical that targets somatostatin receptors, into the Japanese healthcare market. All these factors demand the Japan nuclear medicine market.

Moreover, the rising demand for the development of targeted radiopharmaceuticals contributes to Japan nuclear medicine market expansion.

High Cost of Radiopharmaceuticals

The high costs associated with nuclear medicine procedures, including imaging and therapeutic techniques, present a significant barrier to patient accessibility. Nuclear medicine procedures incur various costs, such as those for advanced imaging equipment (like PET and SPECT machines), the production and acquisition of radiopharmaceuticals, and the operational expenses of specialized facilities. The costs for these procedures can range from several hundred to several thousand dollars, depending on their complexity and type. This variability in pricing can discourage patients from pursuing necessary diagnostic tests or treatments.

The average price of diagnostic imaging, radiology, and nuclear medicine equipment is reported to be $58,657. This figure reflects the general cost associated with acquiring various types of imaging technology used in medical diagnostics.

The elevated costs can restrict access for patients, particularly those from lower-income backgrounds or in areas with limited healthcare resources. Many patients may struggle to cover out-of-pocket expenses or may not have sufficient insurance coverage for nuclear medicine procedures, leading to inequities in access to vital diagnostic and therapeutic services.

Nuclear medicine often competes with other imaging techniques like MRI and CT scans, which might be perceived as more affordable options despite their costs. Additionally, the belief that non-radiation-based imaging methods are safer can further decrease demand for nuclear medicine services, especially among cost-sensitive populations. Thus, the above factors could be limiting the Japan nuclear medicine market's potential growth.

Segment Analysis

The Japan nuclear medicine market is segmented based on product type, procedural volume assessment, application, and end-user.

Product Type:

The diagnostics segment is expected to dominate the Japan nuclear medicine market share

The diagnostics segment holds a major portion of the Japan nuclear medicine market share and is expected to continue to hold a significant portion of the Japan nuclear medicine market share during the forecast period.

The diagnostics segment of the Japan nuclear medicine market is a vital area that includes various imaging techniques and radiopharmaceuticals essential for detecting and managing diseases, particularly cancer. This segment prominently features Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), both crucial for accurately identifying tumors, evaluating their progression, and formulating treatment plans.

For instance, F-18 PSMA-1007 PET has emerged as a cutting-edge diagnostic tool specifically designed to detect prostate cancer recurrence and metastasis with high precision. This imaging agent has demonstrated superior detection capabilities compared to traditional methods like CT and bone scintigraphy, underscoring its importance in oncology diagnostics.

Institutions such as St. Luke's MediLocus provide comprehensive PET-CT scan screenings aimed at early cancer detection. These screenings are critical since early diagnosis significantly enhances treatment outcomes. The integration of PET and CT in one system improves imaging quality, facilitating better visualization of tumors.

The ongoing development of new radiopharmaceuticals is expanding the diagnostic capabilities of nuclear medicine. Research into various PET and SPECT tracers is enhancing the visualization of tumor metabolism, receptor activity, and brain function, thereby broadening the scope of nuclear medicine applications.

Furthermore, key players in the country strategies such as partnerships and collaborations would drive this segment growth in the Japan nuclear medicine market. For instance, in October 2024, Curium announced a strategic partnership with PDRadiopharma Inc., a wholly-owned subsidiary of PeptiDream. This collaboration focuses on the clinical development, regulatory filing, and commercialization in Japan of two key radiopharmaceutical agents: 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

Both agents are designed to target the prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells, making them significant for both treatment and diagnostic purposes in prostate cancer management. These factors have solidified the segment's position in the Japan nuclear medicine market.

Competitive Landscape

The major players in the Japan nuclear medicine market include GE Healthcare, Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), Siemens Healthineers, Bracco, CANON MEDICAL SYSTEMS CORPORATION, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), ATOX CO., Ltd., IBA Radiopharma Solutions, JFE Engineering Corporation, and Koninklijke Philips N.V. among others.

Key Developments

  • In November 2024, Akio Ohta, a researcher from Chiyoda Technol Corporation (CTC) in Japan, stated that the company has been collaborating with the National Research and Innovation Agency (BRIN) on the development of extraction technology for Molybdenum-99 (Mo-99) and Technetium-99m (Tc-99m). This collaboration is facilitated through the Japan Atomic Energy Agency (JAEA), indicating a strategic partnership aimed at enhancing the production and availability of these critical isotopes used in nuclear medicine.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan nuclear medicine market report delivers a detailed analysis with 40+ key tables, more than 30 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Procedural Volume Assessment & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Procedural Volume Assessment
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Cancer and Cardiac Disorders and
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Radiopharmaceuticals
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. General and Diagnostic Equipment*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Diagnostics
    • 6.3.1. Single Photon Emission Computed Tomography (SPECT)
    • 6.3.2. Technetium-99m (Tc-99m)
    • 6.3.3. Thallium-201 (Tl-201)
    • 6.3.4. Gallium-67 (Ga-67)
    • 6.3.5. Iodine-123 (I-123)
    • 6.3.6. Others
    • 6.3.7. Positron Emission Tomography (PET)
    • 6.3.8. Fluorine-18 (F-18)
    • 6.3.9. Rubidium-82 (Rb-82)
    • 6.3.10. Others
  • 6.4. Therapeutics
    • 6.4.1. Alpha Emitters
    • 6.4.2. Radium-223 (Ra-223)
    • 6.4.3. Others
    • 6.4.4. Beta Emitters
    • 6.4.5. Iodine-131 (I-131)
    • 6.4.6. Yttrium-90 (Y-90)
    • 6.4.7. Lutetium-177 (Lu-177)
    • 6.4.8. Others
    • 6.4.9. Brachytherapy Isotopes
    • 6.4.10. Cesium-131
    • 6.4.11. Iodine-125
    • 6.4.12. Palladium-103
    • 6.4.13. Iridium-192
    • 6.4.14. Others

7. By Procedural Volume Assessment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedural Volume Assessment
    • 7.1.2. Market Attractiveness Index, By Procedural Volume Assessment
  • 7.2. Diagnostic Procedures*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. SPECT Procedures
    • 7.2.4. PET Procedures
  • 7.3. Therapeutic Procedures

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oncology
  • 8.4. Neurology
  • 8.5. Thyroid Disorders
  • 8.6. Endocrine Tumors
  • 8.7. Lymphoma and Bone Metastasis
  • 8.8. Pulmonary Scans
  • 8.9. Urology
  • 8.10. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Others

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. GE Healthcare*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
  • 11.3. Siemens Healthineers
  • 11.4. Bracco
  • 11.5. CANON MEDICAL SYSTEMS CORPORATION
  • 11.6. Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
  • 11.7. ATOX CO., Ltd.
  • 11.8. IBA Radiopharma Solutions
  • 11.9. JFE Engineering Corporation
  • 11.10. Koninklijke Philips N.V.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us